The progression of the carcinoma with or without metastasis despite castration therapy (androgen deprivation therapy) is termed as castrate-resistant or hormone-resistant cancer and is characterized by rising prostate-specific antigen (PSA) levels with castrate range of testosterone (<50 ng/dl or <1.7 nmol/l) [6-9]. The gene discussed is KLK3; the disease is cancer.